

## **Supplemental Material to:**

**Seley Gharanei, Anna T Brini, Sumathi Vaiyapuri, Abdullah Alholle, Ashraf Dallol, Elena Arrigoni, Takeshi Kishida, Toru Hiruma, Smadar Avigad, Robert Grimer, Eamonn R Maher, and Farida Latif**

**RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma**

**Epigenetics 2013; 8(9)**


**<http://dx.doi.org/10.4161/epi.25617>**

**[http://www.landesbioscience.com/journals/epigenetics/  
article/25617](http://www.landesbioscience.com/journals/epigenetics/article/25617)**

**Supplementary Table 1: Clinicopathological features of Ewing sarcomas analysed in this study**


Gender		Age		primary site		Metastasis At diagnosis		Tumour diameter			Necrosis (%)			Treatment		Median Survival
Male	Female	≥18	<18	axial	non-axial	yes	no	>10cm	<10cm	n/a	>90	<90	n/a	Chemotherapy	Chemo + radiotherapy	in months
31	24	24	31	13	42	21	30	13	17	22	19	15	19	24	30	34

## Supplementary Figure 1




Supplementary Figure 2

2A



2B



2C

